Liminatus Pharma, Inc. (LIMNW) 股票分析

公司概述

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company dedicated to developing novel cancer therapies, specifically focusing on the creation of CD47, a high affinity humanized anti CD47 antibody. This antibody has the potential to translate into clinical applications for CD47 SIRPa blocking and restoring the anti-tumor function, representing the company's core strategic asset. The company operates within a sector and industry classification that is listed as N/A, indicating a specialized position outside standard industry categorizations. Regarding scale, the company's market cap is listed as N/A, its annual revenue is N/A, and it employs only 1 person. These N/A figures for market capitalization and revenue, combined with a single-employee workforce, indicate that the entity is likely in an early developmental phase where traditional financial scaling metrics have not yet been established or reported.

财务健康

The company reports a net income of $-10,206,517 over the trailing twelve months, while its EBITDA stands at $-2,965,984, and revenue is not disclosed. The significant negative net income relative to the EBITDA figure reveals a substantial cost structure burden, likely driven by high research and development expenses typical of pre-clinical biopharmaceutical firms that are not yet generating commercial revenue. Despite the negative earnings, the company maintains a free cash flow of $7.14M, which suggests a degree of financial flexibility potentially derived from prior financing rounds or asset sales, allowing operations to continue despite current cash burn rates. The company holds $337,655 in cash against total debt of $1.44M, resulting in a debt-to-equity ratio that is listed as N/A. Comparing the available cash of $337,655 to the total debt of $1.44M indicates that while the absolute debt level is low, the company's liquidity position is constrained by its current cash reserves. The gross margin, operating margin, and profit margin are all recorded as 0.0%, which indicates that the company has not yet achieved profitability or is operating with minimal revenue generation relative to its cost base. The current ratio is 0.05, which indicates a severe shortage of short-term assets relative to short-term liabilities, signaling potential liquidity challenges in meeting immediate obligations. Furthermore, the return on assets is -62.6%, while return on equity is listed as N/A; these metrics reveal that the company's assets are currently generating negative returns, reflecting the heavy investment phase without corresponding earnings.

估值评估

The trailing P/E ratio and forward P/E ratio are both listed as N/A, meaning that the difference between them cannot be calculated to imply an expected earnings trajectory at this time due to the lack of positive earnings data. The price-to-book ratio is -0.80, which indicates a valuation significantly below the company's book value, a common characteristic for biotech firms with intangible assets that are not fully captured on the balance sheet. The price-to-sales ratio and EV/EBITDA are listed as N/A, suggesting that these alternative valuation metrics are not applicable or calculable given the absence of reported sales figures and the negative earnings profile. The 52-week high is $0.06 and the 52-week low is $0.05, meaning the current price sits at a premium of 20% above the 52-week low and is trading 20% below the 52-week high. The beta value is 0.63, which means the stock price exhibits lower volatility relative to the broader market, moving less than the average market index during periods of fluctuation.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Since the company does not pay dividends, the dividend yield and payout ratio are listed as N/A, indicating that the company reinvests its available resources and any generated cash flow into growth initiatives rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by a reliance on external capital or internal cash reserves to fund operations in the absence of dividend income or established revenue growth metrics. The absence of dividend payouts combined with N/A growth rates underscores the company's status as a capital-intensive entity focused on long-term therapeutic development rather than immediate financial returns.